Gilead to add lipid kinase inhibitors to pipeline via Carna deal

Gilead has partnered with Carna to develop small molecule inhibitors of lipid kinases in the bellwether’s second deal to bolster its cancer portfolio since CEO Daniel O’Day arrived.

Gilead Sciences Inc. (NASDAQ:GILD) will pay Carna Biosciences Inc. (Tokyo:4572) $20 million up front to license worldwide rights to develop and commercialize candidates against an undisclosed target. The biopharma will also gain exclusive access to Carna's lipid kinase drug discovery platform. ...